<DOC>
	<DOCNO>NCT02115347</DOCNO>
	<brief_summary>This study ass pharmacokinetics safety ertugliflozin ( MK-8835 , PF-04971729 ) participant hepatic impairment versus healthy participant . In Part 1 study , participant moderate hepatic impairment ( Child-Pugh score 7-9 ) match healthy participant enrol ; depend result Part 1 , Part 2 may conduct enroll participant mild hepatic impairment ( Child-Pugh score 5-6 ) .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Tolerability Ertugliflozin ( MK-8835/PF-04971729 ) Participants With Hepatic Impairment Healthy Participants ( MK-8835-014 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>ALL PARTICIPANTS : Body Mass Index ( BMI ) 18 40 kg/m^2 ; total body weight &gt; 50 kg ( 110 lb ) Male female reproductive potential If female reproductive potential , agree remain abstinent heterosexual activity agree use partner use 2 method acceptable contraception prevent pregnancy participant receive study medication 14 day last dose study medication PARTICIPANTS WITH NORMAL HEPATIC FUNCTION Healthy normal hepatic function PARTICIPANTS WITH HEPATIC IMPAIRMENT Satisfy criterion ChildPugh classification [ moderate ( Part 1 ) : ChildPugh Scores 79 point , mild ( Part 2 ) : ChildPugh Scores 56 point ] within 14 day administration study medication A diagnosis hepatic impairment due primary liver disease secondary disease Stable hepatic impairment , define clinicallysignificant change disease status within last 30 day On stable dose medication and/or treatment regimen use manage hepatic disease least 4 week prior study start ALL PARTICIPANTS A known hypersensitivity intolerance ertugliflozin SodiumGlucose coTransporter 2 ( SGLT2 ) inhibitor ( i.e. , canagliflozin [ Invokana ] , dapagliflozin [ Farxiga ] , empagliflozin , ipragliflozin ) Febrile illness within 5 day prior first dose study medication Any clinically significant malabsorption condition A positive urine drug screen drug abuse recreational drug Abuse alcohol binge drinking and/or illicit drug use dependence within 6 month study start Treatment investigational drug within 30 day precede first dose study medication Pregnant breastfeeding female Use herbal supplement within 28 day prior first dose study medication Blood donation ( exclude plasma donation ) approximately 1 pint ( 500 mL ) within 56 day prior dose History sensitivity heparin heparininduced thrombocytopenia PARTICIPANTS WITH NORMAL HEPATIC FUNCTION Use prescription drug ( hormonal method birth control allow ) , vitamin , dietary supplement within 7 day prior first dose study medication Positive serology Hepatitis B C PARTICIPANTS WITH HEPATIC IMPAIRMENT Hepatic carcinoma hepatorenal syndrome life expectancy le 1 year Undergone portalcaval shunt surgery History gastrointestinal hemorrhage due esophageal varix peptic ulcer less one month prior study entry Signs significant hepatic encephalopathy Severe ascites and/or pleural effusion A transplant kidney , heart liver Received following medication within 7 day prior first dose study medication study : Other SGLT2 inhibitor ( eg , dapagliflozin , canagliflozin , empagliflozin , ipragliflozin ) ; Any potent drugmetabolizing enzymeinducing drug , include rifampin , phenytoin , carbamazepine ; Probenecid , valproic acid , gemfibrozil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>